Home › Compare › ALLK vs FCPT

ALLK vs FCPT: Dividend Comparison 2026

ALLK yields 607.72% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALLK wins by $286605.30M in total portfolio value
10 years
ALLK
ALLK
● Live price
607.72%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$286605.35M
Annual income
$216,519,218,488.39
Full ALLK calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — ALLK vs FCPT

📍 ALLK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALLKFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALLK + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ALLK pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALLK
Annual income on $10K today (after 15% tax)
$51,656.03/yr
After 10yr DRIP, annual income (after tax)
$184,041,335,715.13/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, ALLK beats the other by $184,041,330,806.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALLK + FCPT for your $10,000?

ALLK: 50%FCPT: 50%
100% FCPT50/50100% ALLK
Portfolio after 10yr
$143302.70M
Annual income
$108,259,612,131.83/yr
Blended yield
75.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

ALLK
Analyst Ratings
5
Buy
5
Hold
1
Sell
Consensus: Buy
Price Target
$109.50
+33172.6% upside vs current
Range: $1.00 — $218.00
Altman Z
-29.6
Piotroski
1/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALLK buys
1
FCPT buys
0
PoliticianChamberTickerTypeAmountDate
Chris Jacobs🏢 House$ALLK▲ Buy$1,001 - $15,0002022-06-16
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALLKFCPT
Forward yield607.72% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$286605.35M ✓$49.1K
Annual income after 10y$216,519,218,488.39 ✓$5,775.28
Total dividends collected$280771.00M ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$109.50 ✓$27.00

Year-by-year: ALLK vs FCPT ($10,000, DRIP)

YearALLK PortfolioALLK Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$71,472$60,771.80$11,401$700.92+$60.1K → ALLK
2$482,407$405,931.79$13,064$864.84+$469.3K → ALLK
3$3,076,811$2,560,635.83$15,051$1,072.48+$3.06M → ALLK
4$18,555,598$15,263,410.61$17,442$1,337.22+$18.54M → ALLK
5$105,882,914$86,028,423.50$20,340$1,677.08+$105.86M → ALLK
6$572,079,610$458,784,892.67$23,880$2,116.57+$572.06M → ALLK
7$2,928,751,131$2,316,625,947.86$28,241$2,689.36+$2928.72M → ALLK
8$14,217,805,100$11,084,041,390.41$33,660$3,442.07+$14217.77M → ALLK
9$65,501,061,274$50,288,009,817.01$40,456$4,439.95+$65501.02M → ALLK
10$286,605,354,052$216,519,218,488.39$49,063$5,775.28+$286605.30M → ALLK

ALLK vs FCPT: Complete Analysis 2026

ALLK — Stock

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Full ALLK Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this ALLK vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALLK vs SCHDALLK vs JEPIALLK vs OALLK vs KOALLK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.